25 research outputs found
Kaplan Meier time to significant fibrosis stratified by sex.
<p>Kaplan Meier time to significant fibrosis stratified by sex.</p
Discrete time proportional hazards models of factors associated with development of significant fibrosis (APRI ≥ 1.5) in follow-up.
<p>Abbreviations: IDU, injection drug use; HCV, hepatitis C virus; cART, combination antiretroviral; PI, protease inhibitor;</p><p>NNRTI, non-nucleoside reverse transcriptase inhibitor; APRI, aspartate aminotransferase to platelet ratio;</p><p>BMI, body mass index; HR, hazard ratio; CI, confidence interval.</p><p>Discrete time proportional hazards models of factors associated with development of significant fibrosis (APRI ≥ 1.5) in follow-up.</p
Sociodemographic and clinical characteristics of HIV-HCV co-infected patients at baseline by sex (2003–2012).
<p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use;</p><p>APRI, aspartate aminotransferase to platelet ratio; AST, aspartate aminotransferase; BMI, body mass index;</p><p>cART, combination antiretroviral; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.</p><p><sup>a</sup>Sum of regimens >100% as some participants are on both PI, NNRTI and/or other cART.</p><p><sup>b</sup>For HCVRNA VL only 166 (34/87 (39%) female and 132/221 (60%) male) had available quantitative HCV RNA values.</p><p>Sociodemographic and clinical characteristics of HIV-HCV co-infected patients at baseline by sex (2003–2012).</p
Efficacy of therapy by regimen in A) in ARV-naive, and B) ARV-experienced, virologically suppressed patients.
<p>Percentage indicated shows subjects with HIV-1 RNA <50 copies/mL at week 48. Studies that were randomised and sufficiently powered for direct comparison of standard and dual therapy regimens are shaded. <sup>1</sup><48 copies/mL; <sup>2</sup>at 96 weeks; <sup>3</sup><40 copies/mL; <sup>4</sup>at 96 weeks; <sup>5</sup><48 copies/mL; <sup>6</sup>at 96 weeks; <sup>7</sup>at 24 months; <sup>8</sup>at 12 months; <sup>9</sup>at week 24; <sup>10</sup><80 copies/mL. ARV, antiretroviral.</p
Study designs for identified trials in ARV-experienced, virologically suppressed patients.
<p>Study designs for identified trials in ARV-experienced, virologically suppressed patients.</p
Results of key virologic endpoints from identified trials in ARV-naive patients<sup>1</sup>.
<p>Results of key virologic endpoints from identified trials in ARV-naive patients<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0148231#t002fn002" target="_blank"><sup>1</sup></a>.</p
Study designs for identified trials in ARV-naive patients.
<p>Study designs for identified trials in ARV-naive patients.</p
Results of key secondary endpoints from identified trials among ARV-experienced HIV-suppressed patients.
<p>Results of key secondary endpoints from identified trials among ARV-experienced HIV-suppressed patients.</p
Flow diagram of literature search for systematic review.
<p>Flow diagram of literature search for systematic review.</p